Page 6,885«..1020..6,8846,8856,8866,887..6,8906,900..»

2 Cell Transplantation studies impact dental stem cell research for therapeutic purposes

Posted: Published on May 10th, 2012

Public release date: 8-May-2012 [ | E-mail | Share ] Contact: David Eve celltransplantation@gmail.com Cell Transplantation Center of Excellence for Aging and Brain Repair Tampa, Fla. (May. 8, 2012) Two studies appearing in a recent issue of Cell Transplantation (20:11-12), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/, evaluate stem cells derived from dental tissues for characteristics that may make them therapeutically useful and appropriate for transplantation purposes. Induced pluripotent stem cells from immature dental pulp stem cells A Brazilian and American team of researchers used human immature dental pulp stem cells (IDPSCs) as an alternative source for creating induced pluripotent stem cells (iPSCs), stem cells that can be derived from several kinds of adult tissues. According to the study authors, production of iPSCs "opens new opportunities for increased understanding of human genetic diseases and embryogenesis" and will likely have a "great impact on future drug screening and toxicology tests." The authors note, however, that the reprogramming methodology for making iPSCs is relatively new and "needs refining" in terms of technique, efficiency and cell type choice. The researchers report that they easily, and in a short time frame, programmed human immature dental pulp stem cells into iPSCs with the hallmarks of pluripotent … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on 2 Cell Transplantation studies impact dental stem cell research for therapeutic purposes

Stem cell collaboration could set stage for company’s growth

Posted: Published on May 10th, 2012

A stem cell breakthrough at UCLA could mark a big step for a biopharmaceutical company to use its proprietary technology to forge partnerships with pharmaceutical companies and other research institutions. Fibrocell Sciences technology isolates, purifies and multiplies a patients fibroblast cells, connective skin cells that make collagen. In a research collaboration with the company, UCLA used the technology to isolate, identify and increase the number of different skin cell types, which lead to two rare adult stem cell-like subpopulations being identified in adult human skin SSEA3-expressing regeneration-associated cells associated with skin regeneration after injuries and mesenchymal adult stem cells. The findings could have broad applications for personalized medicine. Currently, adult stem cells are derived from adipose tissue and bone marrow. Using mesenchymal stem cells would be less invasive and could be more efficient. Mesenchymal stem cells are being used in research to develop osteoblasts, or bone cells; chondrocytes, or cartilage cells; and adipocytes, or fat cells. David Pernock, the chairman and CEO of Fibrocell, said the move could mark a significant step in the companys growth. Advertisement Pernock added: Once we have shown we can produce these stem cells in meaningful quantities safely and efficiently, I think well be in … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Stem cell collaboration could set stage for company’s growth

Seattle Genetics Reports First Quarter 2012 Financial Results

Posted: Published on May 9th, 2012

BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq:SGEN - News) today reported financial results for the first quarter ended March 31, 2012. The company also highlighted the ADCETRIS (brentuximab vedotin) product launch, ongoing and planned clinical development activities and upcoming milestones. First quarter 2012 ADCETRIS net product sales were $34.5 million, an increase of 4 percent from $33.2 million in the fourth quarter of 2011. ADCETRIS gross product sales increased by 12 percent in the first quarter of 2012 compared to the fourth quarter of 2011, but this increase was offset by an expected increase in gross-to-net discount in the first quarter of 2012 driven by Public Health Services program discounts that became effective during January. The commercialization of ADCETRIS continues to be strong, and we are pleased by the acceptance and utilization of ADCETRIS among oncologists and patients with relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL), said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. Our long-term vision for ADCETRIS is to expand its use into earlier lines of HL and sALCL therapy and into other CD30-positive malignancies. To that end, we are conducting a robust clinical development program with ADCETRIS, including … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Seattle Genetics Reports First Quarter 2012 Financial Results

Advanced Cell Technology Announces 2012 First Quarter Results

Posted: Published on May 9th, 2012

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. (ACT; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today first quarter financial results for the period ended March 31, 2012. The Company reported a loss from operations of $(5.4) million compared to a loss from operations of $(4.8) million in the 2011 first quarter.ACTreported a net loss of $(5.7) million or $(0.00) per share, compared to a loss in the same period in 2011 of $(3.3) million, or $(0.00) per share. Net cash used in operations for the 2011 first quarter was $4.8 million, compared to net cash used in operations of $3.4 million in the same period in 2011. The Company ended the 2012 first quarter with cash and cash equivalents of $10.8 million, compared to $13.1 million as of December 31, 2011. Highlights from the first quarter of 2012 included: We are very pleased with our progress in the clinic so far, said Chairman and CEO Gary Rabin. We are encouraged by the results we have seen from the early patients treated in each of our indications, and look forward to completing the trials on schedule. Conference call and Webcast The Company will hold a conference call tomorrow … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on Advanced Cell Technology Announces 2012 First Quarter Results

Stem cell therapy for WCMS student has remarkable results

Posted: Published on May 9th, 2012

When Tyler was born, the umbilical cord was wrapped around his neck, causing a lack of oxygen to his brain that led to Tyler suffering a stroke during delivery. The stroke caused damage to the back of Tylers brain. Tyler was diagnosed with cerebral palsy and his mother, Lisa Biermann, was told to expect the worst: a child who would never walk, talk, or have any chance at a normal life. Lisa refused to give up hope. She tried everything she could to help Tyler. Tyler could not walk because his feet would not sit flat on the floor. She tried botox injections every three months, braces, casts and even ankle cord surgery. Nothing worked. Lisa said Tyler could not communicate with her at all. She never knew when he was in pain because he was unable to tell her. Tyler was considered to be blind, with a prescription that was over nine units nearsighted, and his eyes jumped around. Even with glasses, he could not focus his vision, and doctors did not believe he could see, or ever would see. Until he was 8 years old, Lisa would carry Tyler from his classes at Woodland Park Elementary. When Tyler … Continue reading →

Comments Off on Stem cell therapy for WCMS student has remarkable results

Erectile dysfunction drug may benefit cardiac function in young patients with heart defects

Posted: Published on May 9th, 2012

Public release date: 8-May-2012 [ | E-mail | Share ] Contact: Joey McCool Ryan McCool@email.chop.edu 267-426-6070 Children's Hospital of Philadelphia Sildenafil, also known as the erectile dysfunction drug Viagra, may give a boost to underdeveloped hearts in children and young adults with congenital heart defects. Researchers from The Children's Hospital of Philadelphia report that sildenafil significantly improved echocardiographic measures of heart function in children and young adult survivors of single ventricle heart disease palliation. "Although researchers will need to evaluate clinical benefits over a longer period with a larger number of patients, this finding offers a potential advance in the management of patients with these types of heart defects," said study leader David J. Goldberg, M.D., a pediatric cardiologist at The Children's Hospital of Philadelphia. The study appeared online recently in the journal Pediatric Cardiology. The researchers randomly assigned 27 children and young adults at Children's Hospital to receive either sildenafil or a placebo for six weeks. After a six-week break in treatment, the subjects were switched to the opposite treatment course. The study team used echocardiograms to measure myocardial performance index (MPI), an indicator of the heart's overall ability to pump blood. The patients in this double-blind, short-term study, … Continue reading →

Posted in Erectile Dysfunction | Comments Off on Erectile dysfunction drug may benefit cardiac function in young patients with heart defects

Poptent's amateurs sell cheap commercials to big brands

Posted: Published on May 9th, 2012

Build-a-Bear Workshop was introducing a line of stuffed animals called smallfrys and wanted to reach moms through Facebook. One video used in the online promotion showed a woman pulling up to a fast-food window. Her young daughter requests "a smallfry." When her mom suggests a fruit cup or celery sticks, the daughter says, "Mom, order me a curly-haired bunny in a purple sequined bathing suit." The 45-second smallfrys spot came not from a traditional advertising agency but from Poptent Inc., a "crowdsourced" video production studio that has built a global community of 50,000 writers, directors, cinematographers and animators to create commercials for Build-a-Bear, American Airlines, Dell, Intel, Jaguar, General Mills and others. It's an example of how the Internet has enabled corporations to harness groups of far-flung enthusiasts to perform work once reserved for professionals. Even such creative endeavors as advertising aren't exempt from the growing popularity of crowdsourcing. "We loved the engagement and creativity that the Poptent community could bring to our brand and especially the launch of a new product," said Maxine Clark, Build-A-Bear's founder and chief executive. "It allowed us to stretch our budget." Advertising experts credit Doritos with demonstrating that passionate amateurs could match the creativity … Continue reading →

Posted in Cheap Pharmacy | Comments Off on Poptent's amateurs sell cheap commercials to big brands

Waterville chief offers help for those dealing with pharmacy robberies

Posted: Published on May 9th, 2012

May 7 AMY CALDER Morning Sentinel WATERVILLE A rise in area pharmacy robberies has prompted police Chief Joseph Massey to host a workshop May 31 for pharmacists and others who dispense prescription drugs about what to do before, during and after a robbery. The event will be 9 a.m. to 10 a.m. in the City Council Chambers at The Center, at 93 Main St. Im becoming very concerned that one of those pharmacy robberies is going to lead to serious injury or death to pharmacy staff, customers or even the robber, Massey said Monday. Weve had three recent robberies that made me realize we needed to take a proactive approach to reduce robberies and the likelihood of some injuries during those robberies. Massey said hard narcotics are a powerful motivation for people to rob such facilities. Theyre not asking for anything else except these hard narcotics, he said. Theyre so focused that all they want is those drugs. Those wanting to register are asked to call Masseys executive assistant, Kathleen Kenney-Haley, at 680-4704, or e-mail her at kkenney@waterville-me.gov. The goal of the workshop is to help businesses develop policies and procedures to help reduce the likelihood of a robbery, as … Continue reading →

Posted in Internet Pharmacy | Comments Off on Waterville chief offers help for those dealing with pharmacy robberies

Feds Bust Rogue Internet Pharmacy

Posted: Published on May 9th, 2012

Tyler Wing WGNO News 11:07 p.m. CDT, May 7, 2012 NEW ORLEANS The Drug Enforcement Agency busts an illegal mail-order pharmaceutical drug-ring based in New Orleans. An 18-month investigation reveals 60-year-old Carlton Charles is the accused mastermind behind a rogue internet pharmacy mailing prescription drugs to people all over the nation. Special Agent in Charge Jimmy Fox says drugs were sold to people in all fifty states, They would package it and ship it through one of the national shipping companies. Three others are in custody charged with a long list of crimes including money laundering, and racketeering. Based out of the same building where the Esplanade Pharmacy is now, agents estimate illegal internet sales totaled roughly $16 million. Fox says Charles used seven different websites to peddle the pharmaceuticals, They had conspired with an individual in Seattle, Washington to create a web base. To circumvent law enforcement they would show the IP address as being located in Austin, Texas. The DEA busted the Esplanade Pharmacy two years ago and Charless license to prescribe was revoked. Link: Feds Bust Rogue Internet Pharmacy … Continue reading →

Posted in Internet Pharmacy | Comments Off on Feds Bust Rogue Internet Pharmacy

Navigating the IP Minefield of Human Embryonic Stem Cell Development

Posted: Published on May 9th, 2012

FARMINGTON, Conn., May 8, 2012 /PRNewswire-iReach/ -- Global Information Inc. is pleased to announce two significant new reports Opportunities in Human Embryonic Stem Cell (hESC) ProductsHuman embryonic stem cells (hESCs) are stem cells derived from the inner cell mass of a blastocyst, the stage reached 4 to 5 days after fertilization. They are the most pluripotent of all stem cell types, able to develop into any of over 200 different cell types in the human body, rending them tremendously useful for their therapeutic potential. However, human embryonic stem cell research is heavily encumbered by patents held by the University of Wisconsin's Wisconsin Alumni Research Foundation (WARF), which creates significant challenges for guidance for companies seeking to develop new products. BioInformant's new Opportunities in Human Embryonic Stem Cell (hESC) Products market research report explores the complex IP landscape affecting development of human embryonic stem cell products, providing clear guidance for companies entering or already within the market. Over the past 15 years, WARF has been the major "gatekeeper" in determining which research product companies are able to conduct research, create commercial products, and develop novel therapies using hESCs. To date, WARF has entered into licensing agreements with only 27 commercial partners … Continue reading →

Posted in Cell Medicine | Comments Off on Navigating the IP Minefield of Human Embryonic Stem Cell Development

Page 6,885«..1020..6,8846,8856,8866,887..6,8906,900..»